The Experts below are selected from a list of 111564 Experts worldwide ranked by ideXlab platform
Richard Beasley - One of the best experts on this subject based on the ideXlab platform.
-
Change in biomarkers of type-2 inflammation following severe exacerbations of asthma
Thorax, 2018Co-Authors: Ruth Semprini, Nick Shortt, Stefan Ebmeier, Alex Semprini, Rachel Varughese, Cecile T.j. Holweg, John G. Matthews, James Fingleton, Mark Weatherall, Richard BeasleyAbstract:We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p Trial Registration Number Post-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.
David M. Baguley - One of the best experts on this subject based on the ideXlab platform.
-
Prevalence of tinnitus and/or hyperacusis in children and adolescents: study protocol for a systematic review.
BMJ open, 2015Co-Authors: Susanne Nemholt, Jesper Hvass Schmidt, Niels Wedderkopp, David M. BaguleyAbstract:Introduction There is some debate as to what extent epidemiological data for the prevalence of childhood tinnitus can be relied on. While indications are that the prevalence is relatively high, referral Numbers for children with tinnitus are reported to be low and many of the studies have a Number of methodological difficulties. We describe the protocol of a systematic review aimed at assessing the prevalence of tinnitus and/or hyperacusis in children and young people. Methods and analysis We will include studies of any design (except case reports or case series) comparing the prevalence of tinnitus and/or hyperacusis in children and young people with and without hearing loss, any known external exposure and psychological disorders. We will search the following databases: PubMed, EMBASE and Scopus. No restrictions of language will be applied in the search strategy but during the article selection language is limited to English, German and Scandinavian languages. Primary and additional outcomes will be the prevalence of tinnitus/hyperacusis and the severity, respectively. Ethics and dissemination No ethical issues are foreseen. The results will be published in a peer-reviewed journal and presented at national and international conferences of audiology and paediatrics. Trail Registration Number This review protocol is registered in the PROSPERO International Prospective Register of Systematic Reviews, Registration Number CRD42014013456.
Mark E Engel - One of the best experts on this subject based on the ideXlab platform.
-
Mobile phone text messaging for improving the uptake of vaccinations: a systematic review protocol.
BMJ open, 2014Co-Authors: Robyn Kalan, Charles Shey Wiysonge, Tshepiso Ramafuthole, Kurt Allie, Fatima Ebrahim, Mark E EngelAbstract:Introduction Low vaccine coverage is a major public health concern, the consequences of which contribute to around 1.5 million child deaths from vaccine-preventable diseases. Thus, innovative strategies to rapidly increase coverage and recall rates for vaccinations are urgently required. Mobile text messaging (or short messaging service, SMS) has the potential to help increase vaccination coverage and therefore we propose to conduct a review of the current best evidence for the use of SMS as an intervention to promote vaccination coverage. Methods and analysis This article describes the protocol for a systematic review of the effectiveness of SMS in improving the uptake of vaccination. Primary and secondary outcomes of interest are prespecified. We will preferably include randomised controlled trials (RCTs). However, non-randomised studies (NRS) will be considered if there is an inadequate Number of RCTs. We will search several bibliographic databases (eg,PubMed, EMBASE, CINAHL, CENTRAL, Science Citation Index, Africa-Wide Information and WHOLIS electronic databases and search sources for grey literature. Following data extraction and assessment of risk of bias, we will meta-analyse studies and conduct subgroup analyses, according to intervention subtypes. We will assess clinical heterogeneity and statistical heterogeneity. For outcomes without quantitative data, a descriptive analysis will be used. This review protocol is registered in the PROSPERO International Prospective Register of systematic reviews, Registration Number 2014:CRD42014007531 Ethics and dissemination Ethics is not required for this study, given that this is a protocol for a systematic review, which uses published data. The findings of this study will be disseminated through peer-reviewed publications and conference presentations. We anticipate that the results could be used by researchers and policymakers to help inform them of the efficacy of mobile phone text messaging interventions to promote increased vaccination coverage. Trial Registration Number PROSPERO Registration Number 2014:CRD42014007531.
Chuntao Liu - One of the best experts on this subject based on the ideXlab platform.
-
The efficacy and safety of long-term add-on treatment of azithromycin in asthma: A systematic review and meta-analysis
Medicine, 2019Co-Authors: Xiaohu Wang, Jian Luo, Dan Wang, Bicui Liu, Chuntao LiuAbstract:AbstractAim:Effects of azithromycin on asthma reported in clinical trials are less consistent. We aimed to further clarify the efficacy and safety of azithromycin in treatment of asthma.Methods:The protocol Registration Number was CRD42017074318 (http://www.crd.york.ac.uk/Prospero). We searched PubM
Ruth Semprini - One of the best experts on this subject based on the ideXlab platform.
-
Change in biomarkers of type-2 inflammation following severe exacerbations of asthma
Thorax, 2018Co-Authors: Ruth Semprini, Nick Shortt, Stefan Ebmeier, Alex Semprini, Rachel Varughese, Cecile T.j. Holweg, John G. Matthews, James Fingleton, Mark Weatherall, Richard BeasleyAbstract:We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p Trial Registration Number Post-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.
